

Active substances set

Search phrase: tivozanib hydrochloride monohydrate

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Kidney cancer

**Tivozanib
hydrochloride
monohydrate**

Tivozanib Hydrochloride Monohydrate is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.

 **NO REIMBURSEMENT**

 **ESMO**